Treatment advance for an incurable blood cancer

Researchers are reporting an impressive advance in the treatment of mantle cell lymphoma, a type of blood cancer that is considered incurable. Patients who took the drug ibrutinib in addition to a...

Progress in preventing kidney cancer recurrence

Cancer “adjuvant” therapies are treatments designed to reduce the chances of tumors coming back after surgery. But for decades, attempts to find adjuvant treatments for kidney cancer failed to...

Clinical trial elevates new target for fighting cancers

Researchers have verified a much-needed new target for treating cancers that often become resistant to existing therapies and become deadly. In an early-phase clinical trial, the researchers tested...

How to make more cancers vulnerable to immunotherapies

Cancer immunotherapies called checkpoint inhibitors can bring dramatic, life-saving results – but only for a limited fraction of patients. Aiming to help more patients benefit, researchers in...

Unlocking the combination to target evasive kidney cancers

Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to...

First-in-class drug targets resistant ovarian cancer

Cancer researchers have discovered a way to target a pivotal driver of drug resistance in ovarian cancer, one of the top causes of cancer death in women. The experimental compound, called SU056,...

Beat AML study paves way for precision treatment

Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...

Three questions for radiation oncologist Ravi Chandra

Ravi Chandra, M.D., Ph.D., is an assistant professor of radiation medicine in the OHSU School of Medicine who has a special interest in serving as a bridge between scientists in the lab and the...